Nasdaq auph.
Dec 4, 2023 · The OCUL stock price is -140.48% off its 52-week high price of $7.96 and 39.58% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 808.59K shares. The consensus among analysts is that Ocular Therapeutix Inc (OCUL ...
The fact that multiple Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When ...In trading on Wednesday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $7.70 per share. By ...Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a speculative stock and it's not making any money, said Cramer. He prefers Nokia (NYSE:NOK) over Ericsson (NASDAQ:ERIC).Dec 4, 2023 · Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders Insiders own 2.02% of the company shares, while shares held by institutions stand at 60.74% with a share float percentage of 61.99%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 142 institutions that hold shares in the ... Discover historical prices for AUPH stock on Yahoo Finance. View daily, weekly or monthly format back to when Aurinia Pharmaceuticals Inc. stock was issued.
Find real-time AUPH - Aurinia Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business.VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on ...Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy recommendation. Analyst Price Forecast Suggests 72.67% Upside ...
Back to AUPH Overview. Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or ... Dec 1, 2023 · AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis.
Real time Aurinia Pharmaceuticals (AUPH) stock price quote, stock graph, news & analysis. Principal Financial Group Inc. cut its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 8.4% in the 2nd quarter, according to its most recent filing with the ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is certainly one of the US-listed biotech stocks with significant upside potential as this Canadian biotechnology company, having bolstered its patent ...Jan 12, 2023 · In trading on Thursday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) crossed above their 200 day moving average of $8.57, changing hands as high as $8.92 per share. Aurinia Pharmaceuticals ...
Find the latest news headlines from Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.
May 22, 2023 · Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ...
Dec 1, 2023 · AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis. Oct 30, 2023 · We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a considerable accomplishment. Aurinia ... AUPH Aurinia Pharmaceuticals Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... This section uses the official NASDAQ-supplied short interest and provides some value-added metrics, calculated daily. Short Interest is updated twice monthly on set schedule, but float and shares outstanding are on a different update ...In trading on Wednesday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $7.70 per share. By ...VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third ...Shares of NASDAQ AUPH opened at $9.06 on Monday. The company has a current ratio of 5.77, a quick ratio of 5.33 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.07 and a twelve month high of $12.43. The stock has a 50 day moving average of $7.93 and a two-hundred day moving average of $9.20.
Jun 30, 2023 · June 30, 2023 — 02:07 pm EDT. Below is Validea's guru fundamental report for AURINIA PHARMACEUTICALS INC ( AUPH). Of the 22 guru strategies we follow, AUPH rates highest using our Value Investor ... Aurinia Pharmaceuticals Inc. NASDAQ: AUPH gapped up in heavy volume on the first trading day of the year and hasn’t looked back since. The Canadian biotech company launched LUPKYNIS two years ago as the first FDA-approved oral treatment for adults with active lupus nephritis (LN). This autoimmune disease affects more than …ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia welcomes the 2023 updated recommendations from The European ...December 4, 2023. Technologies. Vertex Energy Inc (NASDAQ:VTNR) has a beta value of 1.68 and has seen 0.54 million shares traded in the recent trading session. The company, currently valued at $348.79M, closed the recent trade at $3.73 per share which meant it gained $0.11 on the day or 3.04% during that session.Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...
AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Get the latest Aurinia Pharmaceuticals Inc (AUPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses to Inquire About Securities Class Action Investigation – AUPH March 18, 2022 13:00 ET | Source: The Rosen ...Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ...During the last session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares were 2.07 million, with the beta value of the company hitting 1.26. At the end of the trading day, the stock’s price was $8.64, reflecting an intraday gain of 0.47% or $0.04. The 52-week high for the AUPH share is ...AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Aurinia Pharmaceuticals (NASDAQ:AUPH) Third Quarter 2022 ResultsKey Financial Results. Revenue: US$55.8m (up 280% from 3Q 2021). Net loss: US$8.99m (loss narrowed by 82% from 3Q 2021). US$0.063 ...Aurinia Pharmaceuticals Inc stock price (AUPH) NASDAQ: AUPH. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Aurinia Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.The OCUL stock price is -140.48% off its 52-week high price of $7.96 and 39.58% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 808.59K shares. The consensus among analysts is that Ocular Therapeutix Inc (OCUL ...Total cost of sales and operating expenses for the quarter ended September 30, 2023 was $70.8 million and $65.3 million for the quarter ended September 30, 2022. Total cost of sales and operating ...
Dr_Microbe. This article is a follow-up to my previous coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) and as such may run a little shorter than earlier ones.In particular, today, I'd like to ...
Dec 4, 2023 · The OCUL stock price is -140.48% off its 52-week high price of $7.96 and 39.58% above the 52-week low of $2.00. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.72 million shares traded. The 3-month trading volume is 808.59K shares. The consensus among analysts is that Ocular Therapeutix Inc (OCUL ...
In trading on Monday, shares of Aurinia Pharmaceuticals Inc (Symbol: AUPH) entered into oversold territory, hitting an RSI reading of 28.7, after changing hands as low as $8.86 per share. By ...Aurinia Pharmaceuticals (NASDAQ: AUPH), in its third-quarter earnings call for 2023, reported a significant increase in net product revenue and ongoing expansion efforts, while also revealing that ...Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. The first program, AUR200, was acquired from privately-held ...Analyst's Opinion · Consensus Rating. Aurinia Pharmaceuticals has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Aurinia Pharmaceuticals 22.3 mln share stock offering priced at $6.75, 36% below Monday's closing price. Mar. 14, 2017 at 8:04 a.m. ET by Tomi Kilgore.2 нояб. 2023 г. ... Aurinia Pharmaceuticals (AUPH) reported better-than-expected Q3 2023 financials on Thursday driven by its lupus nephritis therapy Lupkynis.Every investor in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ...SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...Fintel reports that on July 6, 2023, Cantor Fitzgerald reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Overweight recommendation. Analyst Price Forecast Suggests 64.02% Upside
Aurinia Pharmaceuticals (NASDAQ:AUPH) is a biopharmaceutical firm delivering therapies for autoimmune, kidney, and rare diseases with unmet medical needs. In 2021, it introduced Lupkynis ...December 4, 2023. Company. Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has a beta value of 1.39 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $1.27B, closed the recent trade at $8.82 per share which meant it lost -$0.24 on the day or -2.60% during that session.AUPH Aurinia Pharmaceuticals Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... This section uses the official NASDAQ-supplied short interest and provides some value-added metrics, calculated daily. Short Interest is updated twice monthly on set schedule, but float and shares outstanding are on a different update ...SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7 ...Instagram:https://instagram. best advance appsrc stockcliffs natural resources stockcmpy Gainers iSpecimen Inc. (NASDAQ:ISPC) shares climbed 126.5% to $11.12 after the company announced it has been contracted to support new advanced ... january dividend stocksgym business insurance 9. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Burrage Capital owned just over 362,000 shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) on September 30 and was more bullish on the stock during ... best healthcare insurance in california Aurinia Pharmaceuticals ( NASDAQ: AUPH) traded ~5% higher pre-market Thursday after the Canadian biotech increased its full-year guidance and posted better-than-expected financials for Q2 2023 ...We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a considerable accomplishment. Aurinia ...